Combined Hormonal Contraceptive Market

Combined hormonal contraceptive basically made by a combination of an estrogen and a progestogen which are primarily used to prevent unwanted pregnancies. Combined hormonal contraceptives are one of the effective contraceptives in modern medicine. Since late 1950s variety of innovation has been developed to improve the efficacy and safety of combined hormonal contraceptive.

The trends have been shifted towards less androgenic progestogens and lower doses of estrogen and progestogen. Changing in drug doses and modification in drug component with the incorporation of new technologies that can reduce the risk factor and the continuing development of novel delivery systems that can be helpful to fulfill unmet needs of the market.

The other health benefits of combined hormonal contraceptives include they reduce the risk of iron deficiency anemia, endometriosis, used in treating acne vulgaris, irregular menstrual flow, and polycystic ovarian syndrome. The mechanism of combined hormonal contraceptive is inhibition of follicle stimulating hormone and luteinizing hormone.

Ethinylestradiol is the most common estrogen used in combined hormonal contraceptives, whereas other hormones are also used. The combined hormonal contraceptive products are available in various forms whereas pills have the maximum share in the combined hormonal contraceptive market. According to the Association of Women Health, around 100 million women use combined hormonal contraceptives throughout the world.

Different types of pregnancy detection kits are present in the market whereas these kits required minimal healthcare professional assistance for completion of test with high accuracy outcome that is one of the major factors which increases demand of pregnancy test kits.

According to the Health Survey, Majority of women takes combined hormonal contraceptive among those women population who have used pregnancy test kits. The government of different countries initiated various program such as family planning program which including planning, delaying and spacing pregnancies. Subsidies birth control contraceptive available in high population density areas which are linked to improved birth outcomes for babies.

The growth of the combined hormonal contraceptive market is driven by growing predominance and more productive medications with emerging interest in quick substitutes. Reduction in the cost of hospitalization and high efficacy can be the prime driving factors for the growth of the combined hormonal contraceptive market over the forecast period.

In emerging countries, the adoption of combined hormonal contraceptives has increased, along with increasing health consciousness and awareness. Growing menstruating population worldwide and various initiatives taken by the governments, such as birth control and women health awareness programs, are factors expected to increase the usage of combined hormonal contraceptive products globally.

Strategic collaborations and acquisitions among manufacturers are also expected to boost the growth of the combined hormonal contraceptive market. However, side effects related to the combined hormonal contraceptive products can hamper the growth of the combined hormonal contraceptive market.

Combined hormonal contraceptive pills are widely used throughout the world due to their high accuracy (more than 90%) if all the instruction used correctly. Route of administration varies according to characteristics of women who use the combined hormonal contraceptive, non-oral forms are generally less common and information on oral use provides a reasonable proxy for all combined hormonal contraceptive use.

Combined hormonal contraceptive pills hold largest revenue share with significant growth rate. Moreover, the success rate of combined hormonal contraceptive pills is on the higher side of birth control which leads to strong positioning of these segments in the overall market. The success rate of combined hormonal contraceptive is estimated to boost the growth of the market over the forecast period.

The cost of medicine and ease-of-use approach is expected to be a most preferred approach which is usually used to prevent the pregnancy or birth control. Promising revenue growth is considered for the combined hormonal contraceptive market over the forecast period.

Retail pharmacies pose a strong position in the market due to non-prescription use of pattern. This end user shared the significant portion of revenue share in the overall market. However, continuing growth of oral combined hormonal contraceptive, increasing awareness, higher accuracy and birth control program will provide a remarkable growth opportunity for combined hormonal contraceptive in outpatient control program clinics, & home care settings. Further, the growing trend of self-diagnostic & home medical testing as a prognostic approach would flourish the growth of combined hormonal contraceptive.

Based on geography, the global combined hormonal contraceptive market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific and the Middle East & Africa. The pharmaceutical market is rapidly growing at a healthy CAGR.

North America followed by Europe will continue to dominate the global combined hormonal contraceptive market in terms of revenue owing to the presence of a large number of manufacturers, technological advancements with increasing menstruating women population and growing awareness about the combined hormonal contraceptive drugs and treatments.

Furthermore, increasing adaptation of minimally invasive procedure or combined hormonal contraceptive is expected to result in higher demand for and growth of the combined hormonal contraceptive market globally over the forecast period.

The Asia Pacific is expected to be one of the fast-growing regions in the global combined hormonal contraceptive market owing to increasing target population and increasing awareness among healthcare sectors/patients. China and India are expected to create immense growth opportunities for the market players over the forecast period

Some of the key participants identified in the global combined hormonal contraceptive market Agile Therapeutics Inc., Actavis Plc, Bayer Healthcare, Teva Pharmaceutical, Pfizer Inc., and GlaxoSmithKline etc. Combined hormonal contraceptive formulations may carry different brand names in different countries or even within the same country.

However, home care setting offers a global opportunity to its manufacturers, as these are common over the counter medicine globally.

The report covers exhaustive analysis on:

• Combined hormonal contraceptive Market by form, Distribution channel, and region
• Regional level market analysis of North America, Latin America, Europe, Asia Pacific Excluding Japan, Japan, Middle East & Africa by form, Distribution channel and country segments
• Combined hormonal contraceptive Market Dynamics & Opportunity Assessment
• Historical Actual Market Size, 2013 - 2017
• Combined hormonal contraceptive Market Size & Forecast 2018-2028
• Combined hormonal contraceptive Agents Current Trends/Issues/Challenges
• Competition & Companies involved

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape, market structure, regulatory scenario
• Epidemiology outlook for diseases
• Economical spending, regional healthcare outlook, consumer healthcare expenditure
• Availability of drugs, cost of drug, efficacy and consumption of drugs
• Strategies for key players and product offerings, Channel strategies, regional footprint, channel footprint
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance in terms of value and volume

The market sizing of combined hormonal contraceptive will be done by experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. The demand-side approach will be followed to assess the actual market size of combined hormonal contraceptive.

Secondary research is used in the initial phase to identify the feasibility of the target drugs categories and its respective segments, product and service offerings, adoption rate and future impact of new drugs. Additionally, per capita consumption of drugs, key treatment pattern, adoption rate and clinical application of drugs among end users is tracked at a granular level to obtain the most accurate information.

Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information Primary research participants include demand-side respondents such as, physicians, surgeons, nursing managers, clinical specialists, as well as key opinion leaders in addition to supply-side respondents such as drug manufacturers and pharmacist who provide valuable insights on trends, purchasing patterns, compliance rate and associated pricing.